Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
11 2019
Historique:
received: 13 05 2019
revised: 25 07 2019
accepted: 30 07 2019
pubmed: 8 9 2019
medline: 15 4 2020
entrez: 8 9 2019
Statut: ppublish

Résumé

Ovarian carcinoma is associated with the highest mortality of all gynecologic malignancies. Even after optimal treatment, prognosis remains poor. There is no established biomarker to predict individual patient outcome. To evaluate the prognostic significance of PD-1 and PD-L1 expression in tumor tissues from patients with ovarian cancer. Tissue micro-arrays were prepared from routinely formalin-fixed, paraffin-embedded tumor tissues and examined immunohistochemically for the expression of programed cell death protein 1 (PD-1) and one of its ligands (PD-L1) on epithelial tumor cells, as well as on tumor- and stroma-infiltrating immune cells. The presence of PD-1 positive tumor-infiltrating immune cells was significantly associated with prolonged overall survival. PD-1 and PD-L1 positive tumor-infiltrating immune cells were associated with the presence of lymph node metastases and higher tumor grade. Interestingly, the amount of PD-1/PD-L1 positive tumor- and stroma-infiltrating immune cells independent of PD-1 or PD-L1 expression did not show any significant correlation with prognostic variables. Our results highlight the prognostic value of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma. Their association with favorable prognosis supports the hypothesis that the expression of PD-1 and PD-L1 on tumor-infiltrating immune cells represents a strong immune response.

Identifiants

pubmed: 31492714
pii: ijgc-2019-000609
doi: 10.1136/ijgc-2019-000609
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1389-1395

Informations de copyright

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Paul Buderath (P)

Department of Gynecology, University Hospital Essen, Essen, Germany paul.buderath@uk-essen.de.

Fabian Mairinger (F)

Department of Pathology, University Hospital Essen, Essen, Germany.

Elena Mairinger (E)

Department of Pathology, University Hospital Essen, Essen, Germany.

Katharina Böhm (K)

Department of Pathology, University Hospital Essen, Essen, Germany.

Pawel Mach (P)

Department of Gynecology, University Hospital Essen, Essen, Germany.

Kurt Werner Schmid (KW)

Department of Pathology, University Hospital Essen, Essen, Germany.

Rainer Kimmig (R)

Department of Gynecology, University Hospital Essen, Essen, Germany.

Sabine Kasimir-Bauer (S)

Department of Gynecology, University Hospital Essen, Essen, Germany.

Agnes Bankfalvi (A)

Department of Pathology, University Hospital Essen, Essen, Germany.

Daniela Westerwick (D)

Department of Pathology, University Hospital Essen, Essen, Germany.

Thomas Hager (T)

Department of Pathology, University Hospital Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH